Low blood level of tumour suppressor miR-5193 as a target of immunotherapy to PD-L1 in gastric cancer.
Hajime KamiyaShuhei KomatsuYusuke TakashimaRyo IshidaHiroshi ArakawaKeiji NishibeppuJun KiuchiTaisuke ImamuraTakuma OhashiHiroki ShimizuTomohiro AritaHirotaka KonishiAtsushi ShiozakiTakeshi KubotaHitoshi FujiwaraShigeki YagyuTomoko IeharaEigo OtsujiPublished in: British journal of cancer (2023)
Low blood levels of miR-5193 are associated with GC progression and poor outcomes and could be a target of nucleic acid immunotherapy in GC patients.